Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PROCEPT BioRobotics

Explore full profile

Surgical robotics company enabling better patient care by developing transformative solutions in urology

Redwood City, United StatesFounded 2009Biotech & Life Sciences
Valuation $892M Market cap · 2026
Revenue $397M Latest reported FY
Total funding $100–500M Disclosed equity funding

About PROCEPT BioRobotics

PROCEPT BioRobotics is a pioneering medical technology company specializing in the development of advanced robotic solutions for the treatment of benign prostatic hyperplasia (BPH). BPH is a common condition in older men that causes enlargement of the prostate gland, leading to uncomfortable urinary symptoms. The company's flagship product, the AquaBeam Robotic System, performs Aquablation therapy, which is a minimally invasive surgical procedure that uses a combination of real-time imaging, robotics, and waterjet technology to remove prostate tissue with high precision.

Read full description

PROCEPT BioRobotics primarily serves urologists and healthcare institutions that treat patients suffering from BPH. The company operates in the medical device market, focusing on innovative surgical solutions that improve patient outcomes and streamline surgical procedures.

The business model of PROCEPT BioRobotics revolves around the sale and distribution of the AquaBeam Robotic System and associated consumables. The company generates revenue through the initial sale of the robotic system to hospitals and clinics, as well as recurring revenue from the sale of disposable components required for each procedure. Additionally, PROCEPT offers training and support services to ensure that healthcare providers can effectively utilize their technology.

PROCEPT BioRobotics has established itself as a leader in the field by providing a solution that offers predictable and reproducible outcomes, reducing the risk of complications and improving the quality of life for patients. The company's technology has been recognized and included in clinical practice guidelines, further solidifying its position in the market.

Source: Dealroom company data

At a glance

Founded
2009
Headquarters
Redwood City, United States
Listing
IPO 2021
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later10 investors entered at this stage

Employees mapped 900 incl. 5 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
9 countries with
team presence
🇺🇸 United States94.6%
🇬🇧 United Kingdom3.8%
🇯🇵 Japan0.7%
🇨🇦 Canada0.1%
🇩🇪 Germany0.1%
Top 5 of 9 shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States82.7%
🇨🇦 Canada8.2%
🇦🇺 Australia2.7%
🇬🇧 United Kingdom1.8%
🇮🇳 India0.9%
Top 5 markets shown

Patents

Estimated portfolio value
$54M

33 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about PROCEPT BioRobotics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PROCEPT BioRobotics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.